PT  - JOURNAL ARTICLE
AU  - YOSUKE ATSUMI
AU  - MASAKATSU NUMATA
AU  - KEISUKE KAZAMA
AU  - SHINNOSUKE KAWAHARA
AU  - MIHWA JU
AU  - KENTA IGUCHI
AU  - SHO SAWAZAKI
AU  - TORU AOYAMA
AU  - AYAKO TAMAGAWA
AU  - SUMITO SATO
AU  - AKIO HIGUCHI
AU  - NOBUHIRO SUGANO
AU  - TENI GODAI
AU  - HIROSHI TAMAGAWA
AU  - HIROYUKI SAEKI
AU  - TAKASHI OSHIMA
AU  - MANABU SHIOZAWA
AU  - NORIO YUKAWA
AU  - YASUSHI RINO
TI  - Can D3 Lymph Node Dissection for Patients With Colon Cancer With a Poor C-Reactive Protein/Albumin Ratio Improve Survival Outcomes?
AID  - 10.21873/anticanres.15326
DP  - 2021 Oct 01
TA  - Anticancer Research
PG  - 5097--5106
VI  - 41
IP  - 10
4099  - http://ar.iiarjournals.org/content/41/10/5097.short
4100  - http://ar.iiarjournals.org/content/41/10/5097.full
SO  - Anticancer Res2021 Oct 01; 41
AB  - Aim: D3 lymph node dissection (LND) for stage II and III colon cancer has been shown to improve prognosis, however, it generally increases surgical stress. Studies have reported that the C-reactive protein/albumin ratio (CAR) may be a useful inflammatory-nutritional biomarker to predict postoperative complications and poor prognosis for with various types of cancer. Our purposes were to assess the short- and long-term outcomes of D3 LND in patients with a high preoperative CAR (≥ 0.04). Patients and Methods: This was a retrospective cohort analysis reviewing a prospectively collected database of Yokohama City University and three affiliated hospitals. A total of 449 patients with stage II or III colon cancer with high CAR who underwent primary resection with D2 or D3 LND were identified between 2008 and 2020. The primary and secondary outcomes of interests were the 3-year recurrence-free survival and postoperative complication rates. Results: After propensity matching, 230 patients were evaluated. There was no significant difference between the D3 and D2 groups in the rate of postoperative complications overall (14.8% versus 11.3%, p=0.558), however, the incidence of anastomotic leakage tended to be greater in the D3 group (9.6% versus 2.6%, p=0.050). The long-term findings showed that there was no significant difference between the two groups (3-year recurrence-free survival rate: 77.2% versus 77.2%, p=0.880). Conclusion: D3 LND did not improve survival outcomes for patients with colon cancer with a poor CAR in this study. D2 LND may be a treatment option for patients with stage II-III colon cancer with a high preoperative CAR.